http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226
Miansong Zhang,Mengke Yao,Airong Jia,Yaping Shi,Xinfeng Bai,Xue Liu,Tingting Cui,Xin Liu,Changheng Liu 한국식품과학회 2021 Food Science and Biotechnology Vol.30 No.13
The soluble dietary fiber from Asparagus officinalis(ASDF) was successively prepared using enzymolysiscombined with spray-drying technology. Highperformanceliquid chromatography analysis showed thatASDF contained two polysaccharide fractions with theaverage molecular weight of 2.77 9 105 and6.44 9 103 Da, and was composed of mannose, rhamnose,galacturonic acid, glucose, galactose, and arabinose with amolecular ratio of 19.93:1.02:1.94:32.17:1.00:1.91,respectively. ASDF showed potential in vitro antioxidantactivities. The oral administration of ASDF significantlyreduced the levels of total cholesterol, triglyceride, andlow-density lipoprotein cholesterol in HD-induced miceserum. Furthermore, 16S rRNA gene sequencing analysisshowed that ASDF significantly affected the compositionof intestinal microbiota, especially reducing the Firmicutes/Bacteroidotetes ratio and the relative abundances ofDesulfobacterota, Proteobacteria, Actinobacteriota andincreasing that of Muribaculaceae, Bacteroides, and Alloprevotella. These results demonstrated that the intake ofASDF could regulate intestinal microbiota and serum lipidlevels in hyperlipidemic conditions.